Premium
Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors
Author(s) -
Yabe Hiroki,
Tsukahara Tomohide,
Kawaguchi Satoshi,
Wada Takuro,
Torigoe Toshihiko,
Sato Noriyuki,
Terai Chihiro,
Aoki Masaya,
Hirose Shigemichi,
Morioka Hideo,
Yabe Hiroo
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21829
Subject(s) - cd8 , human leukocyte antigen , immunohistochemistry , medicine , sarcoma , immune system , monoclonal antibody , immunology , biopsy , hla g , antibody , antigen , cancer research , pathology
Abstract Background Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T‐cell infiltration has yet to be reported. Methods Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti‐HLA class I monoclonal antibody (mAb) EMR8‐5 and anti‐CD8 mAb, respectively. Results Expression of HLA class I was negative in 10 tumors and down‐regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down‐regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients. Conclusions Our results suggested that CD8+ T cell‐mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT. J. Surg. Oncol. J. Surg. Oncol. 2011; 103:380–385. © 2010 Wiley‐Liss, Inc.